Medical Device Trials vs. Drug Trials: The Difference Is a Skillset, Not a Scale

By Tracy Case, MS, MBA, with Genice Gallegos contributing

Unlike a drug, which is administered, a medical device is operated or applied as part of a procedure. That single distinction is the reason a contract research organization built for pharmaceutical trials is not simply a lighter or heavier version of one built for medical devices. It is a different kind of team doing a different kind of work. When we first meet a device sponsor, many do not yet see why that difference is decisive. They assume a capable CRO is a capable CRO, and that device experience is a preference rather than a requirement. The trials that struggle tend to be the ones where that assumption went unexamined until the first human cases exposed it.

Here is the argument in one line. A traditional pharmaceutical trial is primarily protocol-driven. Once a subject is enrolled and dosed, execution becomes relatively standardized. A device trial is protocol plus procedural execution, where outcomes often depend on operator skill, device performance, and procedural nuances. From that starting point, the rest of the trial has to adapt, from how you select and qualify a site to who monitors the study, and each of those choices calls for a specific competency to run it well.

The skillset divide starts before the clinic

For many high-risk and complex devices, the divide is most pronounced one phase upstream, in preclinical and GLP work. The preclinical CRO shapes the study design, model, and is almost entirely responsible for its execution, which has significant impact on the trajectory of the product development likelihood of success. For a cardiovascular device, for example, choosing the right animal model is a matter of anatomic and surgical judgment, aortic diameter, coronary ostia height, vessel wall thickness, and even animal temperament, not a default large-animal setup. Selecting a preclinical key opinion leader is about finding a clinician who thinks like an engineer and holds a whole-team view, not the most recognizable name on the conference stage. And the false economy of buying preclinical work on price alone shows up later as a learning-curve tax paid in the clinic.

In other words, the same skillset divide that shapes how a trial is run already shapes the preclinical phase that comes before it. When preclinical and clinical competencies live in the same organization, the trial inherits procedural intelligence the sponsor would otherwise have to rediscover in human trials. Related reading: The Outsized Impact Optimized Preclinical Studies Have in Clinical Trials and Post-Market Adoption, The Strategic Science of Optimal Preclinical Model Determination, and What Makes an Excellent Preclinical KOL for Medical Devices.

Four places the difference shows up, and what each demands

1. The product does not run itself

Pharmaceutical products, including drugs, biologics, and vaccines, are generally administered according to a defined treatment regimen. Medical devices, including implantable devices, procedural devices, SaMD, and IVDs, encompass a much broader range of technologies and modes of use. Many require implantation, operation, programming, interpretation, or integration into a clinical procedure or workflow. For operator-dependent devices in particular, proficiency can improve with repetition, creating a learning curve that can directly influence study outcomes.

Device trials also tend to enroll fewer subjects while carrying significantly more operational nuance, procedural requirements, and device-specific contingencies than their subject count would suggest.

The competency this requires is layered. At the base, technical aptitude and the ability to understand engineering concepts. On top of it, an understanding of the procedure, the device technology, relevant anatomy, clinical workflow, and physician behavior. And running through all of it, the critical thinking to adapt to real-world procedural variability rather than assuming a predictable playbook.

What it protects: successful advancement into the next phase, and ultimately regulatory clearance, because the evidence reflects the device performed well under its intended use rather than the device used for the first time.

2. Getting into the site is a different problem

In a drug trial, site selection emphasizes research experience and patient access. A device trial asks more of a site. Selection weighs research experience plus procedural expertise, equipment, environmental footprint, imaging capabilities, physician proficiency, and access to multidisciplinary teams. Qualification then goes further still, into a detailed evaluation of, for example, procedural facilities, cath labs, ORs, imaging capabilities, inventory management, and the experience of the physicians who will perform the cases. Institutional approval can require a Value Analysis Committee, a Technology Assessment Committee, supply chain, and biomedical engineering, and recruitment is frequently physician-driven because candidacy is a procedure-by-procedure judgment.

The competency this requires is the ability to assess technical and procedural capabilities and to evaluate procedural workflows and infrastructure, not just research infrastructure.

What it protects: timely site activation, realistic and efficient enrollment, procedural consistency, data quality and lower drop-out, because sites are chosen and prepared for what the procedure actually needs.

3. The team has to speak device

A drug trial’s clinical knowledge base centers on disease state, drug mechanism, dosing, administration and its anticipated safety. A device trial adds another layer of knowledge: disease state plus device engineering, usability, human factors, and procedural medicine. A strong pharma monitor brings GCP and trial-management depth; a device monitor needs that plus procedural, anatomical, and device knowledge, enough to read an operative report and assess technical performance. Site initiation reflects the same gap. Beyond protocol and GCP training, it extends to device handling, troubleshooting, implantation techniques, logistics, and procedural workflows, and proctoring is common rather than rare. Physician engagement is active throughout the study, not delegated to the site.

The competency this requires is the ability to discuss technology credibly with physicians, surgical staff, and engineers, paired with genuine training and presentation skill.

What it protects: satisfied sites and investigators, the same theme that runs through our preclinical work, because a team that can hold its own in the room, and train the room, earns the confidence of the people running the cases.

4. The data and the rules are device-specific

Drug trials center on CRF-based clinical data under ICH-GCP. Device trials require additional data streams and controls: imaging that may support primary endpoint assessment, device accountability down to serial and lot numbers, device malfunctions, deficiencies, explants and returns. They also operate within a regulatory framework that may include ISO 14155, MDR, and IDE requirements. The competency this requires is device regulatory expertise and the ability to integrate clinical, imaging, procedural, and device data steam into a combined clinical evidence package.

What it protects: regulatory clearance or approval, because the evidence package answers the questions device reviewers actually ask. For more on the standard that governs this work, see our piece on ISO 14155:2026 .

A side-by-side view

A compressed view of the framework. The full version follows as a companion reference.

The commercial reality most medical device sponsors feel compared to pharma

Many emerging and mid-sized device sponsors operate with lean teams; and they are frequently more cost-conscious and capital constrained than large pharmaceutical organizations. CRO interaction often occurs directly with founders, engineers, and executives rather than through multiple layers of clinical management. In this setting, a CRO is expected to bring strategic value, not just execution capacity. The competency that matters is a consultative, versatile partner who can carry ownership across functions. Choosing on price alone tends to be a false economy, because any initial savings may be quickly outweighed if a trial has to pause, retrace its steps, or revisit technical, regulatory or operational questions that could have been addressed earlier.

Why it all comes back to adoption

Every competency above protects a link in the path from clinical development to successful adoption: feasible study execution, efficient enrollment, high retention, engaged and satisfied sites and investigators, credible clinical evidence, regulatory success, and finally physician’s confidence in the device and adoption. Successful adoption begins long before launch, determined by the quality and strength of the clinical evidence and the confidence of the physicians who help generate and apply it.

That is why the real question a device sponsor should ask a prospective CRO is not “can you run a trial.” It is “does your team have the device-specific competencies this program requires.” At Veranex, that profile is not assembled per project. Preclinical, regulatory, clinical, commercialization expertise exists within one connected ecosystem, so the expertise that shapes your model and first-in-human plan continuous to support your device through clinical development and adoption.

If you are planning a device trial or evaluating whether your current path is set up for the outcomes that matter, we would welcome the conversation.